Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20629567 | 0.86 | PIK3CA (0.39) | ELANECTSLCTSBCTSKPIK3CA | |
| SCHEMBL23394429 | 0.84 | PIK3CA (0.32) | ELANEPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL14899633 | 0.82 | ELANE (0.39) | ELANE | |
| SCHEMBL18771789 | 0.81 | PIK3CA (0.36) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3C3 | |
| SCHEMBL8055611 | 0.80 | ELANE (0.42) | ELANE | |
| SCHEMBL14232792 | 0.80 | ELANE (0.42) | ELANE | |
| SCHEMBL806180 | 0.80 | ELANE (0.42) | ELANE | |
| SCHEMBL30556768 | 0.78 | CTSL (0.37) | ELANECTSLCTSBCTSK | |
| SCHEMBL26119261 | 0.78 | ELANE (0.38) | ELANECTSLCTSBCTSK | |
| SCHEMBL26120954 | 0.78 | ELANE (0.40) | ELANECTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |